Pharmaceuticals, Biotechnology & Life Sciences

Recordati’s 2025 results show 6% revenue growth and 15% EBITDA lift, driven by Specialty & Primary Care and a breakthrough Rare Diseases therapy, positioning the firm for 2027 gains.

Qiagen’s strategic position amid the Danaher‑Masimo deal shows how diagnostics firms can thrive by leveraging regulatory strengths and exploring cross‑sector partnerships to stay competitive in a consolidating market.

Regeneron’s biopharma strategy focuses on high‑growth cardiovascular, ocular, and niche biologics, balancing R&D costs, value‑based pricing, and competitive pressures for long‑term revenue gains.

Sanofi’s Phase 2b duvakitug data boost IBD prospects, a Hyderabad GCC expansion cuts costs, and new RSV vaccine Beyfortus targets a $2.8 billion market. Click to see how these moves could generate $1.1 billion annual revenue.

IQVIA’s AI strategy faces scrutiny as TD Cowen cuts its target, while a partnership with Isdin could unlock consumer‑health growth – can the company monetize AI amid regulatory pressure?

Discover how Sartorius AG’s new SBTi‑validated climate targets and upcoming AGM set the stage for EU‑aligned growth, ESG leadership, and future green investment plans.

Discover how Bayer’s multi‑billion‑dollar Roundup settlement reshapes its legal risk, finances, and pharma‑agri strategy—and what it means for investors.

Merck KGaA reveals its voting‑rights structure under German securities law, boosting transparency, investor confidence, and governance clarity in pharma‑chemicals.

Danaher’s $9.9 B cash takeover of Masimo boosts its acute‑care diagnostics, adding high‑margin pulse‑oximetry tech and a 3–5 % EBITDA lift in 12‑18 months.

Galderma names Luigi La Corte as CFO, bringing 30 years of global finance expertise to strengthen its dermatology portfolio, investor confidence, and long‑term growth.